Outcomes With Drug-Eluting Versus Bare-Metal Stents in Saphenous Vein Graft Intervention. Results From the STENT (Strategic Transcatheter Evaluation of New Therapies) Group

JACC: Cardiovascular Interventions

Volumn 2, Issue 11, 2009, Pages 1105-1112

  Brodie, Bruce R ^a   Wilson, Hadley ^b   Stuckey, Thomas ^a   Nussbaum, Marcy ^c   Laurent, Sherry ^c   Bradshaw, Barbara ^a   Humphrey, Angela ^c   Metzger, Chris ^d   Hermiller, James ^e   Krainin, Fred ^f   Juk, Stanley ^g   Cheek, Barry ^h   Duffy, Peter ⁱ   Simonton, Charles A ^b  

^a LeBauer Cardiovascular Research Foundation   (United States)

^b CAROLINAS MEDICAL CENTER   (United States)

^c R Stuart Dickson Institute for Health Studies   (United States)

^d Wellmont Holston Valley Medical Center   (United States)

^e Indiana Heart Institute   (United States)

^f McLeod Health   (United States)

^g Sisters of Charity Providence Hospitals   (United States)

^h High Point Regional Health System   (United States)

ⁱ Moore Regional Hospital   (United States)

Author keywords

drug eluting stents; saphenous vein grafts

Indexed keywords

AGED; ARTICLE; BARE METAL STENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DRUG ELUTING STENT; FEMALE; HEART INFARCTION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT SAFETY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SAPHENOUS VEIN GRAFT; STENT THROMBOSIS; THERAPY EFFECT; TREATMENT OUTCOME; VEIN GRAFT DISEASE;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ARTERY BYPASS; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; FEMALE; GRAFT OCCLUSION, VASCULAR; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; METALS; MIDDLE AGED; MYOCARDIAL INFARCTION; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; SAPHENOUS VEIN; STENTS; THROMBOSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 70449486864     PISSN: 19368798     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcin.2009.08.020     Document Type: Article

References (29)

1. Stone G.W., Moses J.W., Ellis S.G., et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 356 (2007) 998-1008
2. Spaulding C., Daemen J., Boersma E., Cutlip D.E., and Serruys P. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356 (2007) 989-997
3. Brilakis E.S., Lichtenwalter C., de Lemos J.A., et al. A randomized-controlled trial of a paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft lesions: The SOS (stenting of saphenous vein grafts) trial. J Am Coll Cardiol 53 (2009) 919-928
4. Vermeersch P., Agostoni P., Verheye S., et al. Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts. J Am Coll Cardiol 48 (2006) 2423-2431
5. Vermeersch P., Agostoni P., Verheye S., et al. Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts. J Am Coll Cardiol 50 (2007) 261-267
6. Lee M.S., Shah A.P., Aragon J., et al. Drug-eluting stenting is superior to bare metal stenting in saphenous vein grafts. Catheter Cardiovasc Interv 66 (2005) 512-513
7. Ge L., Iakovou I., Sangiorgi G.M., et al. Treatment of saphenous vein graft lesions with drug-eluting stents: immediate and midterm outcome. J Am Coll Cardiol 45 (2005) 989-994
8. Chu W.W., Rha S.W., Kuchulakanti P.K., et al. Efficacy of sirolimus-eluting stents compared with bare metal stents for saphenous vein graft intervention. Am J Cardiol 97 (2006) 34-37
9. Hoffmann R., Pohl T., Köster R., Blindt R., Boeckstegers P., and Heitzer T. Implantation of paclitaxel-eluting stents in saphenous vein grafts: clinical and angiographic follow-up results from a multicenter study. Heart 93 (2007) 331-334
10. Ellis S.G., Kandzari D., Kereiakes D.J., et al. Utility of sirolimus-eluting Cypher stents to reduce 12-month target vessel revascularization in saphenous vein graft stenoses: results of a multicenter 350-patient case-control study. J Invasive Cardiol 19 (2007) 404-409
11. Applegate R.J., Sacrinty M., Kutcher M., Santos R., Gandhi S., and Little W. Late outcomes of drug-eluting versus bare metal stents in saphenous vein grafts: propensity score analysis. Catheter Cardiovasc Interv 72 (2008) 7-12
12. Gioia G., Benassi A., Mohendra R., Chowdhury K., Masood I., and Matthai W. Lack of clinical long-term benefit with the use of a drug eluting stent compared to use of a bare metal stent in saphenous vein grafts. Catheter Cardiovasc Interv 72 (2008) 13-20
13. Okabe T., Lindsay J., Buch A.N., et al. Drug-eluting stents versus bare metal stents for narrowing in saphenous vein grafts. Am J Cardiol 102 (2008) 530-534
14. Assali A., Raz Y., Vaknin-Assa H., et al. Beneficial 2-years results of drug-eluting stents in saphenous vein graft lesions. Euro Intervention 4 (2008) 108-114
15. Kaplan S., Barlis P., Kiris A., Dimopoulos K., Celik S., and Di Mario C. Immediate procedural and long-term clinical outcomes following drug-eluting stent implantation to ostial saphenous vein graft lesions. Acute Card Care 10 (2008) 88-92
16. Ramana R.K., Ronan A., Cohoon K., et al. Long-term clinical outcomes of real-world experience using sirolimus-eluting stents in saphenous vein graft disease. Catheter Cardiovasc Interv 71 (2008) 886-893
17. Lozano I., García-Camarero T., Carrillo P., et al. Comparison of drug-eluting and bare metal stents in saphenous vein grafts. Immediate and long-term results. Rev Esp Cardiol 62 (2009) 39-47
18. Simonton C.A., Brodie B.R., Cheek B., et al. Comparative clinical outcomes of paclitaxel and sirolimus-eluting stents. Results from a large prospective multicenter registry-STENT Group. J Am Coll Cardiol 50 (2007) 1214-1222
19. Brodie B.R., Stuckey T., Downey W., et al. Outcomes and complications with off-label use of drug-eluting stents: results from the STENT (Strategic Transcatheter Evaluation of New Therapies) Group. J Am Coll Cardiol Intv 1 (2008) 405-414
20. D'Agostino Jr. R.B. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 17 (1998) 2265-2281
21. Safian R.D. Accelerated atherosclerosis in saphenous vein bypass grafts: a spectrum of diffuse plaque instability. Prog Cardiovasc Dis 44 (2002) 437-448
22. Ellis S.G., Brener S.J., DeLuca S., et al. Late myocardial ischemic events after saphenous vein graft intervention-importance of initially "non-significant" vein graft lesions. Am J Cardiol 79 (1997) 1460-1464
23. Keeley E.C., Velez C.A., O'Neill W.W., and Safian R.D. Long-term clinical outcome and predictors of major adverse cardiac events after percutaneous intervention on saphenous vein grafts. J Am Coll Cardiol 38 (2001) 659-665
24. Bittl J.A. Drug-eluting stents for saphenous vein graft lesions: the limits of evidence. J Am Coll Cardiol 53 (2009) 929-930
25. Kimura T., Yokoi H., Nakagawa Y., et al. Three-year follow-up after implantations of metallic coronary artery stents. N Engl J Med 334 (1996) 561-566
26. Park D., Hong M., Mintz G.S., et al. Two-year follow-up of the quantitative angiographic and volumetric intravascular ultrasound analysis after nonpolymeric paclitxel-eluting stent implantation: late "catch-up" phenomenon from the ASPECT Study. J Am Coll Cardiol 48 (2006) 2432-2438
27. Brilakis E.S., and Berger P.B. Should bare metal or drug-eluting stents be used during PCI of saphenous vein graft lesions: waiting for Godot?. Catheter Cardiovasc Interv 72 (2008) 815-818
28. Pfisterer M., Brunner-La Rocca H.P., Buser P.T., et al. Late clinical events after clopidogrel discontinuation might limit the benefit of drug-eluting stents. An observational study of drug-eluting stents versus bare-metal stents. J Am Coll Cardiol 48 (2006) 2584-2591
29. Eisenstein E.L., Anstrom K.J., Kong D.F., et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 297 (2007) 159-168